Skip to content
Disclosery

EXANE DERIVATIVES: LII position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of EXANE DERIVATIVES on LII, newest first. How the timeline and the estimate are built.

EXANE DERIVATIVES held 3 LII shares at 2022-06-30 per its 13F-HR filed 2022-07-12.

the latest 13F is the newest step

  1. period ended2022-06-30
    13F 3 shares
    Change vs previous 13F -16 shares

    <0.01% of the 13F portfolio, value $620.

    13F-HR 0001623883-22-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2022-03-31
    13F 19 shares
    Change vs previous 13F -1,194 shares

    <0.01% of the 13F portfolio, value $4,899.

    13F-HR 0001623883-22-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2021-12-31
    13F 1,213 shares
    Change vs previous 13F +30 shares

    0.1% of the 13F portfolio, value $393,434.

    13F-HR 0001623883-22-000002 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2021-09-30
    13F 1,183 shares
    Change vs previous 13F +170 shares

    0.09% of the 13F portfolio, value $347,991.

    13F-HR 0001623883-21-000008 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2021-06-30
    13F 1,013 shares
    Change vs previous 13F -1,145 shares

    0.08% of the 13F portfolio, value $340,532.

    13F-HR 0001623883-21-000006 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  6. period ended2021-03-31
    13F 2,158 shares
    Change vs previous 13F not available

    0.2% of the 13F portfolio, value $672,381.

    13F-HR 0001623883-21-000004 filed by EXANE DERIVATIVES
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).